Various Radiopharmaceuticals

The Department of the Army Medical Command has issued a Special Notice regarding its intent to sole source a firm-fixed-price call order to RLS Inc. for various FDA-approved radiopharmaceuticals. The Medical Readiness Contracting Office-West plans to award this contract under the authority of 10 United States Code 3204(a)(1), which allows for sole source procurement when only one reasonable source is available. The contract will cover specific radiopharmaceutical products including I-131 (initial and additional mCi), PYP, DMSA dose, and Table 1 Products such as Illucix, Netspot, Locametz, and Detectnet. The period of performance is scheduled from October 1, 2025, through September 30, 2026. The applicable NAICS code is 325412 (Pharmaceutical Preparation Manufacturing) with a size standard of 1,300 employees.

The purpose of this Special Notice is to formally announce the government's determination that RLS Inc. is the only reasonable source available for these specialized radiopharmaceutical products, thereby justifying the sole source approach rather than competitive bidding. The contracting officer has made this determination based on the unique nature of the required products and RLS Inc.'s capabilities to fulfill the government's needs. The contract award is expected to occur on or about September 15, 2025, with interested parties having until July 25, 2025, to respond to this notice. The government has specified that no requests for capability briefings or telephonic inquiries will be honored during this process. This procurement represents a non-competitive opportunity limited to RLS Inc., as the government has determined that no other contractor possesses the necessary qualifications or resources to provide these specific radiopharmaceutical products.